INTRODUCTION

Gutjnl-2014-308735). (http://dx.doi.org/10.1136/gutjnl-2014-308735).

Department of Medicine, The University of Chicago, Chicago, Illinois, USA
2Departments of Pathology, University of Chicago, Chicago, Illinois, USA
3Departments of Microbiology and Immunology, Indiana University School of Medicine — South Bend, South Bend, Indiana, USA

Correspondence to
Dr David Boone, Departments of Microbiology and Immunology, Indiana University School of Medicine, 1234 N. Notre Dame Ave., South Bend, IN 46617, USA; daboone@iu.edu

Received 29 October 2014
Revised 8 December 2014
Accepted 11 December 2014
Published Online First 2 February 2015

ABSTRACT

Objective ATG16L1 is an autophagy gene known to control host immune responses to viruses and bacteria. Recently, a non-synonymous single-nucleotide polymorphism in ATG16L1 (Thr300Ala), previously identified as a risk factor in Crohn’s disease (CD), was associated with more favourable clinical outcomes in thyroid cancer. Mechanisms underlying this observation have not been proposed, nor is it clear whether an association between Thr300Ala and clinical outcomes will be observed in other cancers. We hypothesised that Thr300Ala influences clinical outcome in human colorectal cancer (CRC) and controls innate antiviral pathways in colon cancer cells.

Design We genotyped 460 patients with CRC and assessed for an association between ATG16L1 Thr300Ala and overall survival and clinical stage. Human CRC cell lines were targeted by homologous recombination to examine the functional consequence of loss of ATG16L1, or introduction of the Thr300Ala variant.

Results We found an association between longer overall survival, reduced metastasis and the ATG16L1 Ala/Ala genotype. Tumour sections from ATG16L1 Ala/Ala patients expressed elevated type I interferons (IFN-I)-inducible, MxA, suggesting that differences in cytokine production may influence disease progression. When introduced into human CRC cells by homologous recombination, the Thr300Ala variant did not affect bulk autophagy, but increased basal production of type I IFN. Introduction of Thr300Ala resulted in increased sensitivity to the dsRNA mimic poly(I:C) through a mitochondrial antiviral signalling (MAVS)-dependent pathway.

Conclusions The CD-risk allele, Thr300Ala, in ATG16L1 is associated with improved overall survival in human CRC, generating a rationale to genotype ATG16L1 Thr300Ala in patients with CRC. We found that Thr300A alters production of MAVS-dependent type I IFN in CRC cells, providing a mechanism that may influence clinical outcomes.

ORIGINAL ARTICLE

The Thr300Ala variant in ATG16L1 is associated with improved survival in human colorectal cancer and enhanced production of type I interferon

Wesley A Grimm,1 Jeannette S Messer,1 Stephen F Murphy,1 Thomas Nero,1 James P Lodolce,1 Christopher R Weber,2 Mark F Logsdon,1 Sarah Bartulis,1 Brooke E Sylvester,1 Amanda Springer,1 Urszula Dougherty,1 Timothy B Niewold,1 Sonia S Kupfer,1 Nathan Ellis,1 Dezheng Huo,1 Marc Bissonnette,1 David L Boone3


Significance of this study

What is already known on this subject?

▸ ATG16L1 is a core autophagy protein.
▸ A genetic non-synonymous polymorphism in ATG16L1 causing an amino acid change T300A is associated with risk for Crohn’s disease (CD).
▸ ATG16L1 also has functions not related to autophagy.

What are the new findings?

▸ Patients with colorectal cancer who have the CD-associated ATG16L1 T300A variant have better long-term survival than patients who have the T300-associated genotype.
▸ Human cells genetically engineered to have the T300A mutation produce more type I interferon than parental cells without the mutation.
▸ The T300A mutation results in higher type I interferon production by a mitochondrial antiviral signalling (MAVS)-mediated signalling pathway.

How might it impact on clinical practice in the foreseeable future?

▸ Patients with colorectal cancer with T300A mutation may derive more benefit from adjuvant-based therapies targeting the mitochondrial MAVS antiviral pathway.

autophagy.1 2 In addition to roles in autophagy, core autophagy proteins, including ATG16L1, ATG5 and ATG12, serve non-autophagy functions such as regulation of innate immune signalling and control of viral replication.3-5 A single-nucleotide polymorphism (SNP) (at rs2241880) in ATG16L1 encoding a Thr300A amino acid substitution has been previously implicated in Crohn’s disease (CD).6 7 Several studies have shown that the T300A variant does not alter bulk autophagy in human cells,2 8 9 suggesting that a non-autophagic function of T300A may underlie its association with CD as well as other human diseases. In a recent study, ATG16L1 T300A was associated with
more favourable clinical outcomes in patients with thyroid carcinoma.10 Whether this association is specific to thyroid cancer or can be found in other malignancies is unknown. Furthermore, potential functions of T300A in cancer cells that may account for this observation have not been proposed.

Type I interferons (IFNs) are essential for the initiation of antiviral immunity, but also participate in antitumour host responses.11 Type I IFN inhibits cancer cell growth,12,13 reduces metastasis,14–16 and increases antitumor host immunity.17–20 Type I IFN-I are a class of α-helical cytokines represented by several semi-homologous IFN-α genes and a single IFN-β. IFN-α/β are produced primarily in response to cytosolic viral dsRNA and 5′triphosphate ssRNA, but also dsDNA and lipopolysaccharide in some cell types.11 Toll-like receptor 3 (TLR3) and mitochondrial antiviral signalling protein (MAVS) pathways are the primary routes leading to phosphorylation of interferon regulatory factors (IRFs, including IRF3, IRF7 and IRF3) and downstream transcription of type I IFNs.11 Activation of MAVS occurs when the cytosolic helicases retinoic acid inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5) bind to viral dsRNAs, leading to interaction of homotypic caspase recruitment domain (CARD domain) and oligomerisation of MAVS on the surface of the mitochondria.21–23

Given the known role of ATG16L1 in regulation of host immune responses in the GI tract, we hypothesised that the T300A variant is associated with altered clinical outcomes in colorectal cancer (CRC). To test this, we examined 460 patients treated at the University of Chicago and identified a beneficial effect of ATG16L1 Ala/Ala genotype on overall survival. We found that fewer metastatic cancers are diagnosed among patients carrying the ATG16L1 Ala/Ala genotype, and that tumour sections from ATG16L1 Ala/Ala patients express elevated IFN-I-inducible genes. When introduced into human CRC cells by homologous recombination, T300A resulted in increased production of IFN-I. Cultured CRC cells expressing T300A displayed increased sensitivity to the dsRNA mimic poly(I:C) through a MAVS-dependent pathway. Thus, ATG16L1 T300A is associated with increased overall survival in human CRC patients, reduced metastasis and elevated MAVS-dependent IFN-I in human CRC cells. These results may have applications regarding the use of oncolytic viruses and p(I:C) as an immunoadjuvants to cancer therapy.

MATERIALS AND METHODS

Please refer to the online supplementary methods section for a description of patient selection criteria, statistical analysis, and other methods and reagents that could not be outlined here due to space constraints.

Isolation of mitochondrial membranes

Briefly, cells were washed twice in ice-cold phosphate-buffered saline, collected in sucrase buffer (320 mM sucrose, 1 mM EDTA, 10 mM Tris–HCl (pH 7.4)), and subject to 10–15 strokes using a Dounce-type homogeniser. Nuclei were cleared twice from homogenates by centrifugation at 3300 rpm at 4°C, and the mitochondrial membrane fraction was pelleted by a single centrifugation at 12 000 rpm (4°C, 20 min). Cytosolic fractions were collected and membrane pellets washed in sucrase buffer once before lysis in radioimmunoprecipitation assay buffer, protein quantification and immunoblotting.

IFN-induced GTP-binding protein Mx1 (MxA) immunohistochemistry scoring

Patient tissues were obtained from the Human Tissue Resource Center at the University of Chicago. Tissues examined were derived from surgically resected tumours from patients diagnosed with invasive colon cancer. These slides were processed and stained for MxA as described above. MxA scoring was performed by a board-certified, trained pathologist who was blinded to patient genotypes and other clinical data. Slides were scored for MxA expression within cancer epithelium on a scale of 1–4 related to the extent of MxA positivity. 1=<5% positive, 2=<10% positive, 3=<30% and 4=>30% positive. When biological replicates (two tumours per patient) were available, both tumours were stained for MxA protein and scores were averaged to produce a single value per patient. Values were plotted and statistical significance was determined using Fisher’s exact test using STATA.

WISH cell stimulation

WISH cells are a HeLa cell line (ATCC, CCL–25) highly sensitive to stimulation with IFN-I and are used to assay IFN-I activity as previously described.24 Human recombinant IFN-β is used as a positive control. Briefly, conditioned media was collected from cells cultured in 6-well plates after reaching 75% confluence. Afterwards cells were dissociated and quantitated using a haemocytometer for normalisation. Prior to stimulation, 0.5×10^6 WISH cells were seeded in 6-well plates. On the following day, conditioned media was used to stimulate WISH cells for 4 h. After stimulation, media was aspirated and cells were immediately lysed using Trizol reagent (Invitrogen). RNA was isolated according to manufacturer’s instructions and used for subsequent cDNA synthesis. Real-time PCR was performed to evaluate induction of IFN-I sensitive genes.

RESULTS

Patient demographics

In a cohort of 460 patients diagnosed with invasive CRC at the University of Chicago Medical Center between 1992 and 2012, 56% (n=258) were Caucasian and 44% (n=202) African-American. Mean age of diagnosis was 64.5 years (range 21–93) and was greater in African-Americans compared with Caucasians (67.4 vs 62.1, one-way analysis of variance p<0.001). Allelic frequencies at rs2241880 did not differ significantly from those found in public databases available (dbSNP) (see online supplementary table S1). In agreement with published data (National Center for Biotechnology Information dbSNP), genotypic frequencies were significantly different when comparing African-American and Caucasian individuals with CRC, the Ala/Ala genotype (GG) being less prevalent in the former (13% vs 28%, p<0.001, see online supplementary table S2). Comparing the clinicopathology of disease in Caucasians and African–Americans revealed fewer rectal cancers diagnosed in African–Americans (p<0.001); however, there were no differences in tumour stage or grade at diagnosis, receipt of radiation and/or chemotherapy, or histopathological features of disease with respect to race (see online supplementary table S2).

Association of ATG16L1 T300A with prolonged overall survival

Mean age of diagnosis did not differ significantly by ATG16L1 genotype (see online supplementary table S2). Overall mean follow-up was 40.7 months (range, 0.98–173) and did not differ by race (p=0.76) (see online supplementary table S2). However,
follow-up time was significantly increased in Ala/Ala patients with colon cancer \((p=0.048)\) (see online supplementary table S3) but not rectal cancer. Over the period of observation, there were 129 deaths from all causes. Disease-specific mortality data were not available for this cohort. The Kaplan–Meier method was used to estimate of survival probability with respect to ATG16L1 genotype while adjusting for race and location of the primary tumour (see online supplementary figure S1). Improved overall survival of patients with CRC was observed in Ala/Ala individuals, which reached statistical significance when plotted in a recessive model \((p=0.044, \text{ figure 1})\). These results suggest that estimated survival is improved in patients carrying the Ala/Ala genotype \((\text{GG})\) in ATG16L1.

Prognostic factors were evaluated by univariate Cox regression. This method identified a survival benefit in patients with CRC carrying the ATG16L1 Ala/Ala genotype \((\text{GG})\) \((\text{HR}=0.55, p=0.017)\) in addition to other prognostic factors, including age, race, stage, grade and location of the tumour (see online supplementary table S4). Multivariate analysis indicated that ATG16L1 genotype was no longer a significant prognostic factor with respect to overall survival \((\text{HR}=0.73, p=0.22)\) while race, invasive stage and grade remained significant. These data suggest that the T300A variant may not act as an independent factor with respect to overall survival.\(^{23}\) In order to understand the effect underlying an association between ATG16L1 T300A and improved overall survival, we tested whether the T300A polymorphism in ATG16L1 is associated with elevated MxA expression in human CRC.

**Association of ATG16L1 T300A with fewer stage IV colon cancers**

In order to understand the effect underlying an association between ATG16L1 T300A and improved overall survival, we tested for relationships between ATG16L1 genotype and clinicopathology of disease. We did not detect associations between ATG16L1 genotype and radiation/chemotherapy, anatomical site of the primary tumour or tumour grade; however, a trend in fewer cases of metastatic (AJCC Stage IV) cancer among Ala/Ala individuals was noted (see online supplementary table S3). Unstratified analysis using multifactorial logistic regression to control for race, grade and location of the primary tumour revealed a similar trend in fewer stage IV cancers diagnosed in Ala/Ala individuals when analysed under the recessive model, which was significant when restricting the analysis to colon cancers \((\text{OR} 0.30, p=0.017)\) (table 1). Thus, ATG16L1 T300A was not significantly associated with tumour grade or location in this cohort. However, we observed fewer stage IV colon cancers in patients homozygous for T300A, suggesting that differences in cancer progression may account for the association between ATG16L1 T300A and improved overall survival.

Previous studies describe a role for ATG16L1 in regulation of inflammation and antiviral immunity in the intestine\(^{23}\) and specifically in the suppression of a type I and II IFN-related gene signature.\(^{26}\) Thus, we hypothesised that differences in disease-modifying cytokines may underlie the association between the Ala/Ala genotype and prolonged survival. IFN-I is an important antiviral cytokine that initiates antitumor immunity,\(^{19, 20}\) inhibits cancer cell growth\(^{12}\) and metastasis.\(^{16}\) Therefore, we hypothesised that ATG16L1 might regulate production of IFN-I in colon carcinoma cells.

**Table 1** Multifactorial regression of variables with respect to diagnosis with stage IV colon cancer

<table>
<thead>
<tr>
<th>Factor</th>
<th>OR (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATG16L1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genotype</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AA+AG</td>
<td>1*</td>
<td></td>
</tr>
<tr>
<td>GG</td>
<td>0.30 (0.11 to 0.81)</td>
<td>0.017</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;60</td>
<td>1*</td>
<td></td>
</tr>
<tr>
<td>60–70</td>
<td>1.4 (0.62 to 3.1)</td>
<td>0.42</td>
</tr>
<tr>
<td>&gt;70</td>
<td>0.99 (0.48 to 2.0)</td>
<td>0.98</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>1*</td>
<td></td>
</tr>
<tr>
<td>African–American</td>
<td>0.83 (0.46 to 1.5)</td>
<td>0.56</td>
</tr>
<tr>
<td>Grade</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>1*</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>2.0 (0.77 to 5.1)</td>
<td>0.15</td>
</tr>
<tr>
<td>III</td>
<td>2.2 (0.75 to 6.4)</td>
<td>0.15</td>
</tr>
</tbody>
</table>

*Reference.

![Figure 1](http://gut.bmj.com/ on October 22, 2017 - Published by group.bmj.com)
ATG16L1 T300A facilitates type I IFN production in CRC. To understand whether the T300A variant alters cancer cell physiology and production of IFN-I in vitro, we used homologous recombination to introduce this SNP into CRC cells. We also used this method to produce cells that are deficient (−/−) in ATG16L1 expression and autophagy as we have previously described. Cells deficient in ATG16L1 display defects in lipidation of LC3 and an accumulation of p62 indicative of a lack of substrate encapsulation and delivery to the lysosome (see online supplementary figure S3A, left panel). Conversely, bulk autophagy and lipidation of LC3 is not affected by introduction of the T300A variant in CRC cells (see online supplementary figure S3A, right panel). Thus, the T300A variant does not affect bulk autophagy in CRC cells, but may affect autophagy-independent functions.

Due to the negative regulation of MAVS and its cytosolic receptors by ATG5-ATG12 and the potential involvement of ATG16L1 in this complex, we performed mitochondrial fractionation to examine whether cytosolic receptors of MAVS, RIG-I and MDA5, were localised to the mitochondria. In ATG16L1−/− cells, we detected increased RIG-I and MDA5 within mitochondrial fractions, suggesting that ATG16L1 prevents translocation of these cytosolic receptors to the mitochondria (figure 3A). Deficiency in ATG16L1 did not impact mitochondrial mass in CRC cells (see online supplementary figures S3B, S3C) nor does it affect levels of other proteins implicated in regulation of MAVS including mitochondrial elongation factor Tu (TUFM) or ATG5-ATG12 within the crude mitochondrial fraction (NLRX1 was undetectable in these cells).

In contrast, deficiency of ATG16L1 resulted in elevated expression of both cytosolic receptors of MAVS, RIG-I and MDA5, indicative of a type I IFN-stimulated state (figure 3A). Importantly, lentiviral transduction of full-length ATG16L1 into ATG16L1−/− cells suppressed expression of RIG-I compared with empty vector controls (see online supplementary figure S4A). These results suggest that ATG16L1 controls expression of RIG-I and MDA5 and may prevent translocation of these proteins to the mitochondrial compartment where they can activate MAVS signalling.

In order to determine whether elevated expression of RIG-I and MDA5 was coincident with an IFN-I response, we examined expression and translocation of IRF 9 (ISGF3γ) to the nuclear compartment by indirect immunofluorescence. ISGF3γ (p48/IRF9) is part of a trimeric complex that includes heterodimerised STAT1 and STAT2 after their phosphorylation by IFN-dependent Jak kinases. Nuclear translocation of ISGF3γ was observed in cells deficient in ATG16L1 as well as increased expression of ISGF3γ in whole-cell lysates (figure 3B, C).
indicative of a response to IFN-I. In agreement with these results, induction of IFN-I-sensitive genes Mx1 (MxA) and C1orf23 was elevated in WISH cells after stimulation with supernatants collected from ATG16L1−/− compared with ATG16L1+/+ cells (figure 3D). Positive feedback of IFN-I is likely to contribute to elevated expression of ISGF3γ and RIG-I in ATG16L1−/− as these observations could be reproduced in ATG16L1+/+ cells after stimulation with human recombinant IFN-β for 1 (see online supplementary figure S5A) or 6 h (see online supplementary figure S5B). Thus, ATG16L1 suppresses production of IFN-I in CRC cells.

In order to examine whether the T300A variant of ATG16L1 affects the function of ATG16L1 to control production of IFN-I in CRC cells, we performed identical experiments comparing ATG16L1 300A/300A cells to their 300T/300T counterparts. Similar to loss of ATG16L1, introduction of T300A into CRC cells resulted in increased production of IFN-I. Elevated expression and translocation of RIG-I and MDA5 to the mitochondrial fraction were evident in ATG16L1 T300A cells (figure 3E) as well as elevated expression and nuclear translocation of ISGF3γ (figure 3F, G). Finally, supernatants collected from cultured ATG16L1 T300A cells contained elevated IFN-I activity using the WISH bioassay (figure 3H). Together, these data suggest that ATG16L1 functions to restrain production of IFN-I in CRC cells, and this negative regulation is reduced in cells with the T300A variant.

ATG16L1 T300A regulates production of MAVS-dependent type I IFN. Production of IFN-I can occur through two major

Figure 3 T300A impairs the ability of ATG16L1 to negatively regulate production of type I interferon in colorectal cancer cells. (A) Immunoblots of indicated proteins in crude mitochondrial lysates prepared from ATG16L1+/+ and ATG16L1−/− cells (n=3). (B) Immunofluorescence staining for ISGF3γ (green) and Hoechst (blue) in ATG16L1+/+ and ATG16L1−/− cells. (C) Immunoblots of whole-cell lysates prepared from ATG16L1+/+ and ATG16L1−/− cells (n=2). (D) Interferon (IFN) bioassay. Real-time PCR of type I interferon-sensitive genes in WISH cells stimulated with conditioned media collected from ATG16L1+/+ and ATG16L1−/− cells after indicated incubation period (8 or 16 h) (n=2). (E) Immunoblots of indicated proteins in crude mitochondrial lysates prepared from 300T/300T and 300A/300A cells (n=3). (F) Immunofluorescence staining for ISGF3γ (green) and Hoechst (blue) in 300T/300T and 300A/300A cells (n=2). (G) Immunoblots of whole-cell lysates prepared from 300T/300T and 300A/300A cells (n=2). (H) IFN bioassay. Real-time PCR of type I interferon-sensitive genes in WISH cells stimulated with conditioned media collected from 300T/300T and 300A/300A cells after indicated incubation period (8 or 16 h) (n=2). Representative real-time PCR experiment performed in triplicate is shown (***p<0.001, two-way ANOVA). ANOVA, analysis of variance; MAVS, mitochondrial antiviral signalling; MDA5, melanoma differentiation-associated protein 5; RIG-I, retinoic acid inducible gene I.
signalling pathways involving TLR3-TRIF/TRAF3 or RIG-I/MDA5-MAVS.30 These converge on common IRFs, which induce transcription of IFN-α/β. In order to test whether ATG16L1 regulates MAVA-dependent production of IFN-I, we generated stably transduced cell lines expressing scrambled or one of two MAVA-targeted siRNAs and confirmed suppression of MAVA expression by immunoblotting whole cell lysates (figure 4A). Reduction of MAVA expression by 40–50% resulted in decreased expression of both RIG-I and ISGF3 in ATG16L1+/+ and T300A cells, demonstrating that ATG16L1 may regulate IFN-I through the MAVA pathway.

To directly interrogate this pathway, we transfected CRC cells with the MDA5 ligand and dsRNA mimic, polyinosinic-polycytidylic acid (poly(I:C)). As opposed to naked poly(I:C), which stimulates primarily TLR3, transfection of poly(I:C)/LyoVec (Invivogen) is capable of stimulating cytosolic receptors leading to MAVA-dependent production of IFN-I. Compared with ATG16L1+/+ cells, ATG16L1 deficiency led to a dose-dependent induction of IFN-β mRNA in response to poly(I:C)/LyoVec stimulation for 4 h, suggesting that ATG16L1 participates in the response of CRC cells to poly(I:C) (figure 4B). Production of IFN-β mRNA in response to poly(I:C)/LyoVec in ATG16L1+/− cells was blunted by stable transduction of full-length ATG16L1 (Figure 5A). Sensitivity of ATG16L1+/− cells to poly(I:C)/LyoVec could be also be ablated by knock down of MAVA, confirming that the RIG-I/MDA5-MAVS pathway was primarily involved in this response (4C). Likewise, introduction of the T300A variant also sensitised CRC cells to poly(I:C)/LyoVec (figure 4D) in a MAVA-dependent manner (figure 4E). Stimulation of genotypical CRC cell lines with poly(I:C)/LyoVec revealed induction of IFN-β mRNA expression in ATG16L1+/− HCT116 cells and HT-29s, which are Ala/Ala, but not in parental HCT116 (Thr/Thr), SW480 (Thr/Thr) or DLD1 (Thr/Ala) cells (figure 4F). Taken together, these data suggest that ATG16L1 and the T300A variant regulates MAVA-dependent responses to poly(I:C)/LyoVec in CRC cells.

DISCUSSION

While the function of IFN-I in cancer has been appreciated for several decades, challenges related to delivery, efficacy and adverse events have made it difficult to target IFN in cancer therapy.11 31 α-IFN acts as an adjuvant during antitumour vaccination, but use of IFN-α in conjunction with chemotherapy used to treat CRC has not been effective.11–33 Conversely, IFN-α has been used successfully in metastatic melanoma in high doses and in certain types of leukaemia.34–36 It is possible that adverse side effects may limit the potential of treatment with IFN-α to obtain an effective dose and durable response in CRC. Our results suggest that use of IFN-stimulating ligands in CRC therapy may be tailored by genotyping patients for ATG16L1 and potentially other variants that might impact IFN responses in CRC cells. Precisely how IFN-I promote survival in CRC is likely to be complex and involve cell autonomous and non-cell autonomous mechanisms. IFN-I production by a tumour cell would induce the recruitment and activation of immune cells, and the presence of such cells is one of the few variables known to improve the prognostic value of standard pathological assessments of CRC.38

Recent work is beginning to revive interest in targeting IFNs in other types of cancer. In human breast cancer, an elevated IFN-I expression signature is inversely related to bone metastasis recurrence. Cancer cells with reduced production of IFN-I due to lack of IRF7 had higher rates of bone metastasis in mice, suggesting that cancer cell-derived type I IFN might inhibit cancer progression. Oncolytic viruses are also known to preferentially target cancer cells and result in cell lysis due to defective antiviral pathways, whereas non-dysplastic epithelium are not permissive.37 The use of oncolytic viruses as immunoadjuvants in cancer treatment has passed safety and feasibility concerns in preclinical tests38–40 and has shown clinical promise in the treatment of human melanoma according to interim data.41 Activation of MAVA contributes to oncolytic virus-induced apoptosis in murine models of melanoma and orthotopic prostate cancer, identifying the importance of this pathway in the efficacy of oncolytic viruses.42–44 Moreover, a subset of prostate cancer cell lines are resistant to oncolytic viruses in an IFN-I-dependent manner, suggesting that host genetics altering the IFN pathway could impact efficacy of this treatment.44 45 ATG16L1 T300A represents a potential host genetic factor that may increase sensitivity to therapies targeting the RIG-I-MAVS pathway or alter the response to viral infection in cancer cells. With more research studying T300A in various cancer types, genotyping patients for this variant could be important to predicting the efficacy of the aforementioned therapies.

Evidence pointing to a role for ATG16L1 in antiviral immunity is accumulating.4 5 27–46 In the absence of IFN-α/β, ATG16L1 is required for control of viral replication in response to IFN-α/β through unknown autophagy-independent mechanisms.3 ATG16L1-deficient mice succumb to Chikungunya virus infection,46 and colonic tissue lacking ATG16L1 expresses elevated type I and II IFN-related genes including Msx,26 in addition to a CD-like pathology after infection with murine norovirus.25 However, specific functions connecting ATG16L1 to regulation of antiviral immune mechanisms or viral replication have not yet been identified, nor is it understood whether the T300A variant impacts these functions. In a recent study, ATG16L1 was immunoprecipitated in complex with MAVS, suggesting that ATG16L1 and ATG5-ATG12 may act together to regulate production of type I IFN.27 ATG5-ATG12 directly inhibits activation of MAVA and production of type I IFN by interacting with MAVA and RIG-I and preventing association of their homotypic CARD domains in response to viral ligands.4 While ATG16L1 is a known partner of ATG5-ATG12, whether ATG16L1 is also required to regulate MAVA-dependent type I IFN is not known.

How ATG16L1 regulates production of IFN-I in CRC cells is currently under investigation, but previous studies point to both autophagy-dependent and autophagy-independent functions of autophagy proteins in this pathway. One possibility is that ATG16L1 (and T300A) regulates activation of MAVA signalling by altering mitochondrial function. Previous work has identified the importance of both mitochondrial membrane potential (ΔΨm) and mitochondrial fusion in activation of MAVA. This is demonstrated by reduced MAVA activation after ectopic expression of the mitochondrial uncoupling protein, UCP-2, which dissipates ΔΨm.47 In addition, cells lacking mitofusin-1 and mitofusin-2 do not produce IFN-β in response to Sendai virus infection, indicating that mitochondrial fusion could be required for organising a signalling platform on mitochondria.48 In contrast, an accumulation of depolarised reactive-oxygen-producing mitochondria in the context of ATG5 deficiency results in increased IFN-α, which could be repressed by treatment with antioxidants.49 These studies contrast with direct inhibition of RIG-I-MAVS signalling by ATG5-ATG12 in an autophagy-independent manner.4 Moreover, in plasmacytoid dendritic cells, autophagy proteins have been shown to enhance rather than repress production of IFN-I due to their requirement in delivery of viral particles to the endosome where they
are recognised primarily by TLRs rather than RIG-I/MDA5. Thus, autophagy proteins have gene and cell-specific effects related to regulation of IFN-I. In CRC cells, we have not observed a significant accumulation of mitochondria upon ATG16L1. Based on these results, and functional bulk autophagy in T300A cells, we propose that ATG16L1 is likely to

Figure 4 ATG16L1 regulates mitochondrial antiviral signalling (MAVS)-dependent type I interferon (IFN-I) production. (A) Immunoblotting of indicated proteins from whole-cells lysates prepared from ATG16L1 cell panel as indicated. Cells were lentivirally transduced with scrambled or one of two shRNAs targeting MAVS (n=2). (B) Real-time PCR following stimulation of ATG16L1+/+ and ATG16L1−/− cells with poly(I:C) for 4 h (n=2). (C) Real-time PCR following stimulation with 1000 ng/mL poly(I:C) for 4 h of ATG16L1−/− cells stably transduced with either scrambled or MAVS-targeted shRNAs (n=2). (D) Real-time PCR following stimulation of ATG16L1 300T/300T and 300A/300A cells with poly(I:C) for 4 h (n=2). (E) Real-time PCR following stimulation with 1000 ng/mL poly(I:C) for 4 h of ATG16L1 300A/300A cells stably transduced with either scrambled or MAVS-targeted shRNAs (n=2). (F) Real-time PCR following stimulation with 1000 ng/mL poly(I:C)/Lyovec for 4 h in common colorectal cancer cell lines. Representative real-time PCR experiment performed in triplicate is shown (**p<0.01, two-way ANOVA). ANOVA, analysis of variance; RIG-I, retinoic acid inducible gene-I.
ATG16L1 does not appear to alter ATG5-ATG12 protein translation of MA VS-dependent IFN-I. In CRC cells, lack of we have identified a requirement for ATG16L1 in negative regulation of MAvS-dependent IFN-I. In CRC cells, lack of ATG16L1 does not appear to alter ATG5-ATG12 protein expression in mitochondrial fractions, but we cannot rule out the possibility that ATG16L1 regulates IFN-I through its actions on ATG5-ATG12 or other indirect mechanisms.

Contributors Study concept and design: WAG, JSM, SFM, DH, MB, D LB; performed experiments: WAG, JSM, SFM, CRW, BES, KS, JD, DN; contributed key reagents and technical support: TN, JPL, MFL, SB, NE, wrote and edited manuscript: WAG, TBN, SSK, NE, MB, D LB.

Funding Grant support: A083735-01; DK42086; Crohn’s and Colitis Foundation IBD-0259 (to D LB).

Competing interests None.

Patient consent Obtained.

Ethics approval Institutional Review Board of The University of Chicago.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES
35 Vasey PA, Shulman LN, Campos S, et al. Phase I trial of intraperitoneal injection of the E15-B5-kd-gene-deleted adenovirus ONX-015 (d1520) given on days 1

463


The Thr300Ala variant in ATG16L1 is associated with improved survival in human colorectal cancer and enhanced production of type I interferon

Wesley A Grimm, Jeannette S Messer, Stephen F Murphy, Thomas Nero, James P Lodolce, Christopher R Weber, Mark F Logsdon, Sarah Bartulis, Brooke E Sylvester, Amanda Springer, Urszula Dougherty, Timothy B Newold, Sonia S Kuper, Nathan Ellis, Dezheng Huo, Marc Bissonnette and David L Boone

Gut 2016 65: 456-464 originally published online February 2, 2015
doi: 10.1136/gutjnl-2014-308735

Updated information and services can be found at:
http://gut.bmj.com/content/65/3/456

These include:

Supplementary Material
Supplementary material can be found at:
http://gut.bmj.com/content/suppl/2015/02/02/gutjnl-2014-308735.DC1

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Open access (384)
Colon cancer (1547)
Crohn's disease (932)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/